miravirsen

DRUG2 trials

Sponsors

Santaris Pharma A/S

Conditions

Hepatitis CHepatitis C, Chronic

Phase 2

Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects

CompletedNCT01200420

Santaris Pharma A/SHepatitis C

Start: 2010-09-30End: 2011-12-31Updated: 2012-01-31

Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection

Santaris Pharma A/SHepatitis C, Chronic

Start: 2013-06-30End: 2015-01-31Target: 20Updated: 2014-11-18

Related Papers

<i>In Vitro</i> Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122

Antimicrobial Agents and Chemotherapy2014-11-11228 citations

Treatment of HCV infection by targeting microRNA.

2013-03-271650 citations